Alectinib: A Review in Advanced, ALK-Positive NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Drugs"
DOI: 10.1007/s40265-018-0952-0
Abstract: Alectinib (Alecensa®) is a potent and highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor. Oral alectinib monotherapy is approved in the EU as first-line treatment for adults with advanced ALK-positive non-small cell lung cancer… read more here.
Keywords: positive nsclc; nsclc; advanced alk; treatment ... See more keywords
Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.09.127
Abstract: Introduction: A significant portion of NSCLCs with MET proto‐oncogene, receptor tyrosine kinase gene (MET) exon 14 skipping alterations are sensitive to small‐molecule mesenchymal‐epithelial transition tyrosine kinase inhibitors. However, the incidence and management of brain metastases… read more here.
Keywords: brain metastases; positive nsclc; exon positive; cabozantinib ... See more keywords
Brigatinib in Patients With Alectinib‐Refractory ALK‐Positive NSCLC
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.06.005
Abstract: Introduction: The second‐generation anaplastic lymphoma kinase (ALK) inhibitor alectinib recently showed superior efficacy compared to the first‐generation ALK inhibitor crizotinib in advanced ALK‐rearranged NSCLC, establishing alectinib as the new standard first‐line therapy. Brigatinib, another second‐generation… read more here.
Keywords: positive nsclc; alectinib refractory; alk; alk positive ... See more keywords
Abstract 6767: Cancer-associated fibroblasts promote T-cell exclusion and resistance to immunotherapy in non-small cell lung cancer with tertiary lymphoid structures
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6767
Abstract: Background: We and others have reported the major role of mature tertiary lymphoid structures (TLS) in the efficacy of PD-L1 blockade in NSCLC. The objective response rate (ORR) to inhibition of PD1/PDL1 used as single… read more here.
Keywords: positive nsclc; cell; cancer; tls positive ... See more keywords
Pembrolizumab alone or with chemotherapy for PD-L1 positive NSCLC: A network meta-analysis of randomized trials.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.9087
Abstract: 9087 Background: Pembrolizumab (P) has replaced chemotherapy (C) as first-line treatment for advanced non-small cell lung cancer (NSCLC) with tumor PD-L1 expression > / = 50%. Among PD-L1 unselected patients, P+C is superior to C… read more here.
Keywords: network meta; meta analysis; analysis; difference ... See more keywords
Biology and impact of lineage plasticity in ALK-positive NSCLC: a narrative review
Sign Up to like & getrecommendations! Published in 2023 at "Translational Lung Cancer Research"
DOI: 10.21037/tlcr-22-867
Abstract: Background and Objective Lineage transformation is a known mechanism of acquired resistance to targeted therapies in non-small cell lung cancer (NSCLC). Transformation to small cell and squamous carcinoma and epithelial-to-mesenchymal transition (EMT) have all been… read more here.
Keywords: positive nsclc; lineage transformation; biology; alk positive ... See more keywords
Next-generation sequencing to dynamically detect mechanisms of resistance to ALK inhibitors in ALK-positive NSCLC patients: a case report.
Sign Up to like & getrecommendations! Published in 2020 at "Translational lung cancer research"
DOI: 10.21037/tlcr.2020.02.07
Abstract: Tyrosine kinase inhibitors (TKIs) of the anaplastic lymphoma kinase gene (ALK) have significantly improved the quality of life and survival of non-small cell lung cancer (NSCLC) patients whose tumors harbor an ALK translocation. However, most… read more here.
Keywords: alk positive; case; resistance; nsclc patients ... See more keywords
Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Management and Research"
DOI: 10.2147/cmar.s283199
Abstract: Abstract Lorlatinib is an oral third-generation inhibitor of anaplastic lymphoma kinase (ALK) with activity in advanced ALK-positive non-small cell lung cancer (NSCLC) in both the first and subsequent line setting. Superior systemic and intracranial efficacy… read more here.
Keywords: positive nsclc; advanced alk; disease progression; alk positive ... See more keywords
Plain language summary and patient perspective of the European Society for Medical Oncology expert consensus statements on treating EGFR-positive non-small-cell lung cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Future oncology"
DOI: 10.2217/fon-2022-1213
Abstract: WHAT IS THIS SUMMARY ABOUT? This article provides a plain language summary and patient perspective of a new set of recommendations made by the European Society for Medical Oncology (ESMO for short). These recommendations are… read more here.
Keywords: lung cancer; oncology; egfr positive; positive nsclc ... See more keywords
ALK Inhibitors in the Treatment of ALK Positive NSCLC
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2018.00557
Abstract: Background: ALK inhibitors have shown positive advance in the treatment of ALK+ NSCLC. They have achieved better results in prolonging the progression free survival and improving quality of life in comparison to chemotherapy. We have… read more here.
Keywords: positive nsclc; alk inhibitors; alk; treatment alk ... See more keywords
Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.816683
Abstract: Background: Alectinib, a highly selective inhibitor of ALK, is currently used in the first-line setting of untreated advanced ALK-positive NSCLC and in the second-line setting of crizotinib-resistant ALK-positive NSCLC. Despite promising efficacy and tolerability in… read more here.
Keywords: positive nsclc; case; alk positive; alk ... See more keywords